Color Genomics, a Burlingame, Calif.-based startup that has made a name for itself by selling tests for genes that dramatically raise the risk of cancer, is moving into a new area: heart disease. In doing so, it is stepping even more deeply into a raging debate over the medical and economic value of plumbing our DNA.